## Lifang Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4038563/publications.pdf

Version: 2024-02-01

933447 526287 33 812 10 27 citations g-index h-index papers 34 34 34 2055 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): AÂmulticenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology, 2020, 146, 137-146.e3.	2.9	374
2	Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 992-994.	10.5	202
3	Dynamics of Blood Viral Load Is Strongly Associated with Clinical Outcomes in Coronavirus Disease 2019 (COVID-19) Patients. Journal of Molecular Diagnostics, 2021, 23, 10-18.	2.8	34
4	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer Journal, 2021, 11, 131.	6.2	28
5	Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood, 2020, 136, 516-519.	1.4	25
6	The risk factors for mortality of diabetic patients with severe COVID-19: A retrospective study of 167 severe COVID-19 cases in Wuhan. PLoS ONE, 2020, 15, e0243602.	2.5	18
7	Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review. International Journal of Clinical and Experimental Medicine, 2014, 7, 4357-68.	1.3	17
8	Longâ€term outcomes of relapsed/refractory doubleâ€hit lymphoma (r/r DHL) treated with CD19/22 CAR Tâ€cell cocktail therapy. Clinical and Translational Medicine, 2020, 10, e176.	4.0	14
9	Clinical characteristics of hematological patients concomitant with COVIDâ€19. Cancer Science, 2020, 111, 3379-3385.	3.9	14
10	CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2022, 24, 841-849.	0.7	12
11	Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2). Current Cancer Drug Targets, 2019, 19, 729-741.	1.6	11
12	Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience. Transplantation and Cellular Therapy, 2021, 27, 331.e1-331.e7.	1.2	10
13	Does Chronic Sleep Fragmentation Lead to Alzheimer's Disease in Young Wild-Type Mice?. Frontiers in Aging Neuroscience, 2021, 13, 759983.	3.4	10
14	A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. Cancer Medicine, 2021, 10, 4387-4396.	2.8	9
15	Plasma Uric Acid Helps Predict Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2021, 12, 789840.	2.4	8
16	Chronic myeloid leukemia with variation of translocation at (Ph) [ins (22;9) (q11;q21q34)]: a case report. International Journal of Clinical and Experimental Pathology, 2015, 8, 13707-10.	0.5	6
17	Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. International Journal of Clinical and Experimental Pathology, 2014, 7, 4239-46.	0.5	5
18	Investigation of SARS-CoV-2 on Ocular Surface of Coronavirus Disease 2019 Patients Using One-Step Reverse-Transcription Droplet Digital PCR. Infection and Drug Resistance, 2021, Volume 14, 5395-5401.	2.7	5

#	Article	IF	CITATIONS
19	Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report. Frontiers in Oncology, 2022, 12, 817969.	2.8	2
20	In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase. Oncology Letters, 2014, 7, 791-796.	1.8	1
21	Clonal cytogenetic abnormalities are predictor in developing non-Hodgkin lymphomas?. Experimental and Molecular Pathology, 2017, 102, 146-155.	2.1	1
22	Cytogenetics with flow cytometry in lymph node/extranodal tissue biopsies is sensitive to assist the early diagnosis of suspected lymphomas. Annals of Hematology, 2017, 96, 1673-1680.	1.8	1
23	CD41 immune staining of micromegakaryocytes improves the diagnosis of myelodysplastic syndrome and differentiation from pancytopenia. Leukemia Research, 2018, 66, 15-19.	0.8	1
24	A case of a patient characterized by $t(8;22)(p11;q11)$ and BCR/FGFR1 fusion gene, who was successfully treated with haploidentical hematopoietic stem cell transplantation. Hematology, 2021, 26, 691-696.	1.5	1
25	Reinduction chemotherapy regimen involved decitabine and cladribine improves the prognosis of patients with relapsed or refractory acute myeloid leukemia: A preliminary study. International Journal of Cancer, 2021, 149, 901.	5.1	1
26	Clinical efficacy of decitabine‑containing induction chemotherapy in de�novo non‑elderly acute myeloid leukemia. International Journal of Oncology, 2020, 56, 1521-1528.	3.3	1
27	Analysis of prognostic factors in lymphoma patients with bone marrow involvement: a single center cohort study. International Journal of Clinical and Experimental Medicine, 2015, 8, 9676-83.	1.3	1
28	Experiment Therapy of Aplastic Anemia Using Cyclosporin A Combined with IDO Agonist Blood, 2007, 110, 1695-1695.	1.4	0
29	The Complicated Network Structure and Activated Notch Signal Pathway in Embryo Heart of Mouse Provide the Favorable Microenvironment for HSCs Development and Proliferation During E10â^¼E12. Blood, 2011, 118, 4806-4806.	1.4	0
30	Title is missing!. , 2020, 15, e0243602.		0
31	Title is missing!. , 2020, 15, e0243602.		0
32	Title is missing!. , 2020, 15, e0243602.		0
33	Title is missing!. , 2020, 15, e0243602.		O